ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries
Two plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, showing …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
A turning point for pancreatic cancer patients
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
ASCO: AstraZeneca's Imfinzi, Imjudo duo shines in earlier-stage liver cancer
ASCO26: BMS and J&J debut shining multiple myeloma data - Pharmaceutical Technology
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
Akeso, Summit drug extends survival in closely watched lung cancer trial
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3…
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s…
UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST | In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease…
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
All of the regular ASCO abstracts dropped Thursday afternoon. Find updates on potential successors for Pfizer’s blockbuster…
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
